Aureka Biotechnologies
United States, Laguna Hills, CA
About Aureka Biotechnologies
Aureka Biotechnologies is a tech-bio company founded in 2023 with R&D operations in Suzhou and California that develops antibody therapeutics through its proprietary AuraIDE generative-AI platform. The platform pairs foundation models and AI agents with a high-throughput single-cell functional screening system to design differentiated antibodies for cardiometabolic, immune, and central-nervous-system disease targets that are difficult to address with conventional discovery methods. The company has built a BD/NewCo collaboration model with multiple multinational pharmaceutical companies and is preparing its first internally-designed antibody to enter clinical trials.
Latest Funding
Series AAnnounced 2026-04-27
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
5 signals · where the capital is going
Scale dual-continent R&D operations across Suzhou (China) and California (USA) to support the platform and pipeline expansion.
flcube.com
Enhance high-throughput, high-content experimental platform infrastructure that generates the functional data feeding the AI design loop.
vcbeathealth.com
+3 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to Aureka Biotechnologies? You're in the right place.
Knowing they raised is the start. The edge is what's attached to Aureka Biotechnologies.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of Aureka Biotechnologies, and who are their main competitors?
Sign up free to ask AI about Aureka Biotechnologies
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
5Y Capital
Lead investor · Series A
Tech Stack
Nginx
Nuxt.js
Node.js
Key Highlights
AI InsightsSeries A+ extension brings cumulative Series A funding for Aureka Biotechnologies close to USD 100 million within roughly six months of the original Series A.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to Aureka Biotechnologies
Selling to Aureka Biotechnologies? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to Aureka Biotechnologies.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.